ALK and non-small cell lung carcinoma: As summarized above, six treatment regimens employing three different strategies, including neoadjuvant treatment only, adjuvant treatment only, and peri-operative treatment, have been approved by the FDA in patients with resectable stage II and III NSCLC without ALK/EGFR alterations.